Developer docs
API playgroundTry for free, no card

Search company profiles

EonArk

Full company profile

uuid02m5okm

Namestring
EonArk
Legal namestring
Shenzhen EonArk Technology Co., Ltd. (深圳无尽方舟科技有限公司)
Websiteurl
eonark.ai
Company typeenum
Private
Founded yearint
2026
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersShenzhen, China
HQ citystring
Shenzhen
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, longevity biotechnology, biological age testing, precision pet health, cross-species aging research
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Longevity Biotechnology Platform
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Precision Health Products and Services
TypeSubscription Recurring
Description

Precision health services for companion animals including methylation-based biological age testing, genetic risk assessment, health status monitoring, and long-term follow-up interventions. This serves as the early commercial entry point while generating real-world data for R&D.

eonark.ai
2Drug Development and Licensing
TypeLicensing Royalties
Description

Long-term revenue stream from developing anti-aging drugs and interventions based on platform discoveries, targeting the longevity and lifespan extension market.

eonark.ai
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 2 records shown
1Precision Health (精准健康)
Description

Precision health service focused on biological age measurement through methylation detection, genetic risk assessment, health status monitoring, and long-term follow-up for companion animals.

eonark.ai
+1 more record
Core offering1 text field

EonArk builds AI-driven longevity biotechnology products, centered on a proprietary Longevity Foundation Model and the H2P Cross-Species Transfer Learning Model that analyze cross-species, cross-organ, single-cell transcriptomics data to discover anti-aging intervention targets. The platform operates a Wet-Dry-Wet iterative discovery-validation loop and is paired with a Precision Health product line delivering methylation-based biological age testing, genetic risk assessment, and long-term health monitoring for companion animals, plus a Natural Small Molecule Screening Platform for drug discovery.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EonArk operates as an AI-driven longevity biotechnology company with a unified platform architecture centered on the Longevity Foundation Model. The core offering comprises the EonArk AI Platform and H2P Cross-Species Transfer Learning Model, which process single-cell genomic data to discover intervention targets. The Precision Health product line serves as an early commercial entry point for companion animal health, providing methylation-based biological age testing and long-term health monitoring that feeds real-world data back into the R&D platform. The company also operates the Natural Small Molecule Screening Platform (deepnatural.top) for drug discovery, all unified by a wet-dry-wet iterative development approach.

Product and service1 record
1Longevity Foundation Model
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

AI-aging research company deriving intervention targets from longitudinal and single-cell human data; strong overlap with EonArk's AI biology + longevity discovery thesis.

TypeDirect peer
Description

AI-driven aging biology platform that uses ML on omics data to identify and validate intervention targets for age-related diseases; methodologically parallel to EonArk's H2P cross-species target identification approach.

TypeOthers
Description

Public computational chemistry and molecular simulation platform serving pharma R&D; thematically adjacent as an AI/computational-biology infrastructure provider in the drug discovery ecosystem.

TypeBroad incumbent
Description

Multi-billion-dollar longevity biotech pursuing cellular rejuvenation across multiple modalities; competes for the same talent, scientific narrative, and pharma BD EonArk is targeting.

TypeDirect peer
Description

AI-driven drug discovery platform with explicit longevity/anti-aging focus, combining deep generative models with wet-lab validation; closest direct analog to EonArk's Longevity Foundation Model + H2P stack.

TypeBroad incumbent
Description

Alphabet-owned longevity biotech with a broad portfolio approach to aging biology; a reference broad incumbent that anchors the anti-aging category in which EonArk competes.

TypeBroad incumbent
Description

Established AI-driven drug discovery company using high-dimensional biological data and automated wet labs; thematically similar AI-bio convergence but with a broader therapeutic focus than EonArk.

TypeEmerging player
Description

Companion animal longevity pharma developing drugs to extend healthy lifespan in dogs; parallels EonArk's pet health commercial entry and the translational animal-to-human longevity thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EonArk

Longevity Biotechnology Platformeonark.ai

EonArk firmographics

Firmographics
Name
EonArk
Legal name
Shenzhen EonArk Technology Co., Ltd. (深圳无尽方舟科技有限公司)
Website
https://eonark.ai
Company type
Private
Founded year
2026
Operating status
Operating
Ownership category
akta.pro rank

EonArk industry classification

Industry
Product category
Longevity Biotechnology Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Longevity biotechnology
  • Biological age testing
  • Precision pet health
  • Cross-species aging research

Where EonArk is headquartered

Location

Headquarters

HQ city
Shenzhen
HQ country
China
HQ region
Asia

Offices1 record

Markets served

EonArk business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Precision Health Products and Services: Precision health services for companion animals including methylation-based biological age testing, genetic risk assessment, health status monitoring, and long-term follow-up interventions. This serves as the early commercial entry point while generating real-world data for R&D.
  2. Drug Development and Licensing: Long-term revenue stream from developing anti-aging drugs and interventions based on platform discoveries, targeting the longevity and lifespan extension market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

EonArk product offering

Product offering

Core offering

EonArk builds AI-driven longevity biotechnology products, centered on a proprietary Longevity Foundation Model and the H2P Cross-Species Transfer Learning Model that analyze cross-species, cross-organ, single-cell transcriptomics data to discover anti-aging intervention targets. The platform operates a Wet-Dry-Wet iterative discovery-validation loop and is paired with a Precision Health product line delivering methylation-based biological age testing, genetic risk assessment, and long-term health monitoring for companion animals, plus a Natural Small Molecule Screening Platform for drug discovery.

Product overview

EonArk operates as an AI-driven longevity biotechnology company with a unified platform architecture centered on the Longevity Foundation Model. The core offering comprises the EonArk AI Platform and H2P Cross-Species Transfer Learning Model, which process single-cell genomic data to discover intervention targets. The Precision Health product line serves as an early commercial entry point for companion animal health, providing methylation-based biological age testing and long-term health monitoring that feeds real-world data back into the R&D platform. The company also operates the Natural Small Molecule Screening Platform (deepnatural.top) for drug discovery, all unified by a wet-dry-wet iterative development approach.

Differentiator

Problem solved

Functional benefit

Brands

  • Precision Health (精准健康): Precision health service focused on biological age measurement through methylation detection, genetic risk assessment, health status monitoring, and long-term follow-up for companion animals.
  • H2P Cross-Species Transfer Learning Model

Products and services

  • Longevity Foundation Model

Companies that use EonArk

Customer profile

Segments2 records

Ideal customer profiles2 records

EonArk technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

EonArk partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

EonArk competitors and assessment

Company assessment

Direct peers

  • Gero: AI-aging research company deriving intervention targets from longitudinal and single-cell human data; strong overlap with EonArk's AI biology + longevity discovery thesis.
  • BioAge Labs: AI-driven aging biology platform that uses ML on omics data to identify and validate intervention targets for age-related diseases; methodologically parallel to EonArk's H2P cross-species target identification approach.
  • Insilico Medicine: AI-driven drug discovery platform with explicit longevity/anti-aging focus, combining deep generative models with wet-lab validation; closest direct analog to EonArk's Longevity Foundation Model + H2P stack.

Others

  • Schrödinger: Public computational chemistry and molecular simulation platform serving pharma R&D; thematically adjacent as an AI/computational-biology infrastructure provider in the drug discovery ecosystem.

Broad incumbents

  • Altos Labs: Multi-billion-dollar longevity biotech pursuing cellular rejuvenation across multiple modalities; competes for the same talent, scientific narrative, and pharma BD EonArk is targeting.
  • Calico Life Sciences: Alphabet-owned longevity biotech with a broad portfolio approach to aging biology; a reference broad incumbent that anchors the anti-aging category in which EonArk competes.
  • Recursion Pharmaceuticals: Established AI-driven drug discovery company using high-dimensional biological data and automated wet labs; thematically similar AI-bio convergence but with a broader therapeutic focus than EonArk.

Emerging players

  • Loyal for Dogs: Companion animal longevity pharma developing drugs to extend healthy lifespan in dogs; parallels EonArk's pet health commercial entry and the translational animal-to-human longevity thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

EonArk financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EonArk leadership team

Management profile

Number of profiles

Profiles6 records

EonArk funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EonArk M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EonArk

What does EonArk do?

EonArk builds AI-driven longevity biotechnology products, centered on a proprietary Longevity Foundation Model and the H2P Cross-Species Transfer Learning Model that analyze cross-species, cross-organ, single-cell transcriptomics data to discover anti-aging intervention targets. The platform operates a Wet-Dry-Wet iterative discovery-validation loop and is paired with a Precision Health product line delivering methylation-based biological age testing, genetic risk assessment, and long-term health monitoring for companion animals, plus a Natural Small Molecule Screening Platform for drug discovery.

Is EonArk a public or private company?

EonArk is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was EonArk founded?

EonArk was founded in 2026.

Where is EonArk based?

EonArk is headquartered in Shenzhen, China, in the Asia region.

How does EonArk make money?

Two revenue lines are on record. Precision Health Products and Services are the primary driver. The others are drug Development and Licensing.

Who are EonArk's main competitors?

Direct peers on record are Gero, BioAge Labs and Insilico Medicine. Schrödinger is listed as an others. Broad incumbents are Altos Labs, Calico Life Sciences and Recursion Pharmaceuticals. Loyal for Dogs is listed as an emerging player.

Does EonArk have an API?

No public API is recorded for EonArk.

What industry is EonArk in?

EonArk's product category is Longevity Biotechnology Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales